UNITED LAB (03933 HK) Issues Profit Warning, Projects 24.7% YoY Decline in 2025 Net Profit to RMB2.00 Billion

Bulletin Express03-12

The United Laboratories International Holdings Limited (UNITED LAB, 03933 HK) announced that, based on unaudited management accounts, the Group expects to post approximately RMB2.00 billion in profit for the financial year ended 31 December 2025, down about 24.74% from the RMB2.66 billion recorded in 2024.

Management attributed the earnings contraction primarily to weaker pricing in two key business lines: 1. Intermediate Products: segment profit is forecast to fall by about RMB1.60 billion year-on-year. 2. Bulk Medicine: segment profit is projected to decrease by roughly RMB0.40 billion.

Partially offsetting these declines, the Finished Products segment is expected to deliver a profit increase of around RMB1.40 billion, bolstered by approximately RMB1.30 billion in licence-fee income from Novo Nordisk A/S.

The financial figures remain subject to finalisation and audit review. UNITED LAB cautioned shareholders and prospective investors to exercise prudence when trading its shares ahead of the formal 2025 results announcement and annual report release.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178154709?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178154709","market":"us","top_or_hot":-1,"title":"UNITED LAB (03933 HK) Issues Profit Warning, Projects 24.7% YoY Decline in 2025 Net Profit to RMB2.00 Billion","media":"Bulletin Express","content":"<p>The United Laboratories International Holdings Limited (UNITED LAB, 03933 HK) announced that, based on unaudited management accounts, the Group expects to post approximately RMB2.00 billion in profit for the financial year ended 31 December 2025, down about 24.74% from the RMB2.66 billion recorded in 2024.</p>\n<p>Management attributed the earnings contraction primarily to weaker pricing in two key business lines:\n1. Intermediate Products: segment profit is forecast to fall by about RMB1.60 billion year-on-year.\n2. Bulk Medicine: segment profit is projected to decrease by roughly RMB0.40 billion.</p>\n<p>Partially offsetting these declines, the Finished Products segment is expected to deliver a profit increase of around RMB1.40 billion, bolstered by approximately RMB1.30 billion in licence-fee income from Novo Nordisk A/S.</p>\n<p>The financial figures remain subject to finalisation and audit review. UNITED LAB cautioned shareholders and prospective investors to exercise prudence when trading its shares ahead of the formal 2025 results announcement and annual report release.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UNITED LAB (03933 HK) Issues Profit Warning, Projects 24.7% YoY Decline in 2025 Net Profit to RMB2.00 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUNITED LAB (03933 HK) Issues Profit Warning, Projects 24.7% YoY Decline in 2025 Net Profit to RMB2.00 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 18:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The United Laboratories International Holdings Limited (UNITED LAB, 03933 HK) announced that, based on unaudited management accounts, the Group expects to post approximately RMB2.00 billion in profit for the financial year ended 31 December 2025, down about 24.74% from the RMB2.66 billion recorded in 2024.</p>\n<p>Management attributed the earnings contraction primarily to weaker pricing in two key business lines:\n1. Intermediate Products: segment profit is forecast to fall by about RMB1.60 billion year-on-year.\n2. Bulk Medicine: segment profit is projected to decrease by roughly RMB0.40 billion.</p>\n<p>Partially offsetting these declines, the Finished Products segment is expected to deliver a profit increase of around RMB1.40 billion, bolstered by approximately RMB1.30 billion in licence-fee income from Novo Nordisk A/S.</p>\n<p>The financial figures remain subject to finalisation and audit review. UNITED LAB cautioned shareholders and prospective investors to exercise prudence when trading its shares ahead of the formal 2025 results announcement and annual report release.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1178154709","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178154709","pubTimestamp":1773311053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"The United Laboratories International Holdings Limited (UNITED LAB, 03933 HK) announced that, based on unaudited management accounts, the Group expects to post approximately RMB2.00 billion in profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药"},"translate_title":"联邦制药(03933 HK)发布盈利预警预计2025年净利润同比下降24.7%至人民币20.0亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"The United Laboratories International Holdings Limited (UNITED LAB, 03933 HK) announced that, based on unaudited management accounts, the Group expects to post approximately RMB2.00 billion in profit for the financial year ended 31 December 2025, down about 24.74% from the RMB2.66 billion recorded in 2024.\nManagement attributed the earnings contraction primarily to weaker pricing in two key business lines:\n1. Intermediate Products: segment profit is forecast to fall by about RMB1.60 billion year-on-year.\n2. Bulk Medicine: segment profit is projected to decrease by roughly RMB0.40 billion.\nPartially offsetting these declines, the Finished Products segment is expected to deliver a profit increase of around RMB1.40 billion, bolstered by approximately RMB1.30 billion in licence-fee income from Novo Nordisk A/S.\nThe financial figures remain subject to finalisation and audit review. UNITED LAB cautioned shareholders and prospective investors to exercise prudence when trading its shares ahead of the formal 2025 results announcement and annual report release.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178154709","isCrawlerRequest":true}